By Erin Harris, Editor-In-Chief, Cell & Gene
Follow Me On Twitter @ErinHarris_1
Triplet Therapeutics is a biotech leveraging insights from the human genetics of repeat expansion disorders (REDs). The company recently released its preclinical data in Huntington’s disease (HD) for its first clinical candidate TTX-3360. TTX-360, an antisense oligonucleotide, is the first therapeutic candidate with the potential to modify the course of HD and other REDs by targeting the DNA Damage Response pathway. REDs are a group of more than 50 known genetic diseases associated with DNA nucleotide repeats many of which have been shown to lengthen, or expand, in cells over a patient’s lifetime. Irina Antonijevic, M.D., Ph.D., Chief Medical Officer and Nessan Bermingham, Ph.D., CEO, President, and Founder atTriplet Therapeutics explain in detail the pre-clinical data as well as the company’s equity pledge that will help to benefit patients of the RED community.
Further explain the pre-clinical data that is available to illustrate that new insights into the mechanisms of REDs.
Irina Antonijevic, M.D., Ph.D., Chief Medical Officer, Triplet Therapeutics: While the inherited uninterrupted CAG repeat length is the main determinant of age at onset (AAO), it accounts only for around 50–70% of variation in age at onset. The remaining variability is also heritable, indicating the presence of genetic modifier genes that affect disease onset and progression. GWAS have revealed that variability in AAO given the same number of inherited CAG repeats can significantly be attributed to specific genetic modifiers, many of which have been identified to be a part of the DDR (DNA Damage Response) pathway.
Multiple lines of preclinical evidence indicate that lowering of select DDR proteins by ~ 50% halts somatic expansion, including studies in patient-derived cells, and animal models. Human variant analysis of certain DDR genes further indicates that somatic expansion of the HD CAG repeats affects timing of disease onset and progression.
Specifically, recent studies have established that human genetic variants that affect expression of DDR protein MSH3 has an impact on AAO and disease progression in HD and myotonic dystrophy and also affect somatic expansion (measured in blood cells). GWAS, transcriptome-wide association studies, and human variant analyses confirm that these variants acts in a dose-dependent manner: individuals with variants that confer higher expression of MSH3 are associated with earlier AAO and more somatic expansion, and conversely lower expression of MSH3 is associated with later AAO and less somatic expansion. In addition, in HD, the impact of MSH3 expression and somatic expansion has also been shown on disease progression (less MSH3 expression associated with slower disease progression, including in premanifest HD).
Our animal model data with a tool ASO (ASO that binds to mouse MSH3) show that MSH3 lowering by 50% halts somatic expansion in both younger and older mice.
References: Moss et al. 2017; Flower at al. 2019; Ciosi et al. 2019; GeM-HD 2019; Hong et al. 2021; Swami et al. 2009, Wright et al. 2019
Explain the equity pledge to a patient support fund. How will the this benefits the RED community?
Nessan Bermingham, Ph.D., CEO, President, and Founder, Triplet Therapeutics: This patient support fund is at arm’s length and independent of Triplet. We are placing 1% of our equity into an entity (myself and my wife are committing addition consideration into the fund). The intent is for this fund to realize monetary value over time through the sale of the equity (we expect that we will continue to add to this fund as the company continues to grow). The use of the return will be dependent on the people/groups that oversee the fund and what they deem to be an important, unmet, need for patients and their families. One can imagine that this can range from childcare support, travel expenses, diagnostics, palliative care etc. It is not being dictated/determined by Triplet Therapeutics.